^
Association details:
| Biomarker: | BCL2 elevation + IGH elevation |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance
Published date:
11/01/2018
Excerpt:
Secondly, we report the results from the StiL-NHL7-trial including bcl2/IgH analyses of 308 bcl2/IgHpositive patients who received B-R and Rituximab maintenance...High circulating bcl-2/IgH levels in the PB before first line therapy identify a subgroup of patients with advanced FL who have significantly shorter PFS after standard immuno-chemotherapy
DOI:
10.1182/blood-2018-99-118750
Trial ID:
